BRPI1014278A2 - uma nova formulação de metaxalona - Google Patents
uma nova formulação de metaxalonaInfo
- Publication number
- BRPI1014278A2 BRPI1014278A2 BRPI1014278A BRPI1014278A BRPI1014278A2 BR PI1014278 A2 BRPI1014278 A2 BR PI1014278A2 BR PI1014278 A BRPI1014278 A BR PI1014278A BR PI1014278 A BRPI1014278 A BR PI1014278A BR PI1014278 A2 BRPI1014278 A2 BR PI1014278A2
- Authority
- BR
- Brazil
- Prior art keywords
- new
- metaxalone
- formulation
- metaxalone formulation
- new metaxalone
- Prior art date
Links
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229960000509 metaxalone Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2973—Particular cross section
- Y10T428/2978—Surface characteristic
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17228109P | 2009-04-24 | 2009-04-24 | |
| AU2009901743A AU2009901743A0 (en) | 2009-04-24 | A Novel Formulation of Metaxalone | |
| AU2009901743 | 2009-04-24 | ||
| US61/172,281 | 2009-04-24 | ||
| PCT/AU2010/000468 WO2010121324A1 (en) | 2009-04-24 | 2010-04-23 | A novel formulation of metaxalone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1014278A2 true BRPI1014278A2 (pt) | 2016-11-08 |
| BRPI1014278B1 BRPI1014278B1 (pt) | 2020-10-13 |
| BRPI1014278B8 BRPI1014278B8 (pt) | 2021-05-25 |
Family
ID=43010607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014278A BRPI1014278B8 (pt) | 2009-04-24 | 2010-04-23 | método para produzir uma forma de dosagem compreendendo metaxolona, forma de dosagem, composição farmacêutica compreendendo a referida forma de dosagem e uso da mesma |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US20120263760A1 (pt) |
| EP (1) | EP2421530B1 (pt) |
| JP (3) | JP6116243B2 (pt) |
| CN (2) | CN102438621A (pt) |
| AU (3) | AU2010239082B2 (pt) |
| BR (1) | BRPI1014278B8 (pt) |
| CA (1) | CA2759113C (pt) |
| IL (1) | IL215864B (pt) |
| MX (1) | MX360019B (pt) |
| NZ (1) | NZ595903A (pt) |
| WO (1) | WO2010121324A1 (pt) |
| ZA (1) | ZA201108644B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| MX360019B (es) * | 2009-04-24 | 2018-10-15 | Iceutica Pty Ltd | Una formulación novedosa de metaxalona. |
| CN102438594A (zh) | 2009-04-24 | 2012-05-02 | 伊休蒂卡有限公司 | 吲哚美辛的新剂型 |
| SG10201800491RA (en) * | 2013-07-22 | 2018-03-28 | Iceutica Inc | Formulation of metaxalone |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| CN106537128B (zh) | 2014-06-09 | 2021-06-18 | 生物统计股份有限公司 | 用于测量分析物的低成本测试条和方法 |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| CN104758243B (zh) * | 2015-04-01 | 2017-04-12 | 山东司邦得制药有限公司 | 一种治疗皮肤溃疡的蒙脱石外用软膏及其制备方法和应用 |
| US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| WO2017136617A1 (en) | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
| CN114859028A (zh) | 2016-07-19 | 2022-08-05 | 生物统计股份有限公司 | 使用批量可校准测试条测量分析物的方法和系统 |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| WO2019217286A1 (en) * | 2018-05-07 | 2019-11-14 | Prana Biosciences Inc | Metaxalone formulations |
| CN114207101B (zh) | 2019-07-31 | 2024-05-31 | 埃科莱布美国股份有限公司 | 免用个人防护设备的脱灰剂组合物 |
| KR102178885B1 (ko) * | 2020-01-17 | 2020-11-13 | 강현준 | 카프릴산을 포함하는 안정한 해충 방제제 및 이의 제조방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| JP4117811B2 (ja) * | 1997-04-22 | 2008-07-16 | 日本化薬株式会社 | フルタミド製剤及びその製法 |
| MXPA01004381A (es) * | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Composicion de multiparticulado de liberacion modificada. |
| DE10144146A1 (de) * | 2001-09-07 | 2003-04-03 | Wittenstein Ag | Steuerknüppel |
| US6407128B1 (en) * | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
| US7714006B1 (en) * | 2001-12-03 | 2010-05-11 | King Pharmaceuticals Research & Development, Inc. | Methods of modifying the bioavailability of metaxalone |
| GB0219516D0 (en) * | 2002-08-21 | 2002-10-02 | Phoqus Ltd | Fast dissolving and taste masked oral dosage form comprising sildenafil |
| AU2003276688A1 (en) * | 2002-09-02 | 2004-03-19 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition of metaxalone with enhanced oral bioavailability |
| JP2004099442A (ja) * | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
| WO2004058216A2 (en) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
| AU2003230189A1 (en) * | 2003-01-29 | 2004-08-23 | Nitin Bhalachandra Dharmadhikari | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| ATE415946T1 (de) * | 2003-08-08 | 2008-12-15 | Elan Pharma Int Ltd | Neue metaxalon-zusammensetzungen |
| US20050276844A1 (en) * | 2004-03-08 | 2005-12-15 | Spiridon Spireas | Bioavailable compositions of metaxalone and processes for producing the same |
| WO2006009419A1 (es) * | 2004-07-19 | 2006-01-26 | Luis Cordova Boone | Neumáticos con doble banda de rodamiento |
| CA2598204C (en) * | 2004-11-09 | 2015-01-13 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
| US20080292584A1 (en) * | 2005-10-14 | 2008-11-27 | Mutual Pharmaceutical Company, Inc. | Metaxalone products, method of manufacture, and method of use |
| CA2631493A1 (en) * | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| WO2007074477A2 (en) * | 2005-12-29 | 2007-07-05 | Dabur Pharma Limited | Metaxalone polymorphs |
| AU2007264418B2 (en) * | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| US20120160944A1 (en) * | 2009-04-24 | 2012-06-28 | Aaron Dodd | Method for the production of commercial nanoparticle and micro particle powders |
| JP5898613B2 (ja) * | 2009-04-24 | 2016-04-06 | イシューティカ ピーティーワイ リミテッド | 生物学的活性物質の溶解プロファイルを改善するための方法 |
| MX360019B (es) * | 2009-04-24 | 2018-10-15 | Iceutica Pty Ltd | Una formulación novedosa de metaxalona. |
| AP3138A (en) * | 2009-04-24 | 2015-02-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
-
2010
- 2010-04-23 MX MX2011011233A patent/MX360019B/es active IP Right Grant
- 2010-04-23 BR BRPI1014278A patent/BRPI1014278B8/pt not_active IP Right Cessation
- 2010-04-23 EP EP10766517.6A patent/EP2421530B1/en active Active
- 2010-04-23 US US13/266,115 patent/US20120263760A1/en not_active Abandoned
- 2010-04-23 WO PCT/AU2010/000468 patent/WO2010121324A1/en not_active Ceased
- 2010-04-23 JP JP2012506286A patent/JP6116243B2/ja active Active
- 2010-04-23 CA CA2759113A patent/CA2759113C/en not_active Expired - Fee Related
- 2010-04-23 NZ NZ595903A patent/NZ595903A/en not_active IP Right Cessation
- 2010-04-23 CN CN201080017990XA patent/CN102438621A/zh active Pending
- 2010-04-23 CN CN201410145550.2A patent/CN104000785B/zh not_active Expired - Fee Related
- 2010-04-23 AU AU2010239082A patent/AU2010239082B2/en not_active Ceased
-
2011
- 2011-10-23 IL IL215864A patent/IL215864B/en active IP Right Grant
- 2011-11-24 ZA ZA2011/08644A patent/ZA201108644B/en unknown
-
2014
- 2014-04-10 US US14/250,190 patent/US20140302127A1/en not_active Abandoned
- 2014-09-17 AU AU2014227473A patent/AU2014227473B2/en not_active Ceased
-
2015
- 2015-05-19 JP JP2015101975A patent/JP6324925B2/ja active Active
- 2015-12-21 US US14/977,314 patent/US20160108009A1/en not_active Abandoned
-
2016
- 2016-08-19 AU AU2016216723A patent/AU2016216723B2/en not_active Ceased
-
2017
- 2017-04-07 US US15/482,598 patent/US20180009769A1/en not_active Abandoned
- 2017-09-04 JP JP2017169071A patent/JP2018021058A/ja active Pending
-
2018
- 2018-05-03 US US15/970,651 patent/US20180251433A1/en not_active Abandoned
-
2020
- 2020-04-13 US US16/847,628 patent/US20200308123A1/en not_active Abandoned
-
2021
- 2021-05-24 US US17/329,034 patent/US20210403442A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014278A2 (pt) | uma nova formulação de metaxalona | |
| HRP20182200T1 (hr) | Nova protuupalna sredstva | |
| PT2506716T (pt) | Novos compostos tricíclicos | |
| BRPI1014279A2 (pt) | uma nova formulação de meloxicam | |
| DK2542189T3 (da) | Håndprotese | |
| BRPI1012120A2 (pt) | máquina de exercício | |
| DK2427449T3 (da) | Vinylindazolylforbindelser | |
| BR112012006859A2 (pt) | compostos | |
| FR2942627B1 (fr) | Composition de graisse | |
| BRPI1013588A2 (pt) | composição | |
| BRPI1015474A2 (pt) | composição | |
| BRPI1009465A2 (pt) | Formulação | |
| BR112012000657A2 (pt) | novos azabicilohexanos | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| BRPI1011901A2 (pt) | fotoiniciadores | |
| EP2647652A4 (en) | LIGHT-CURABLE COMPOSITIONS | |
| BR112012014028A2 (pt) | uso de uma composição | |
| ME03352B (me) | Brojač | |
| IT1402153B1 (it) | Composizione comprendente un larvicida fotoattivabile | |
| EP2410957A4 (en) | SUPPORT BANDAGE OF THE PLANTAIRE VISOR | |
| PL2408498T3 (pl) | Licznik | |
| BRPI1005290A2 (pt) | composição | |
| BRPI0910630A2 (pt) | utilização de um extrato de mirto como despigmentador | |
| BRPI1006253A2 (pt) | aparelho de exercícios | |
| DK2405753T3 (da) | Insektfrastødende sammensætning |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2667 DE 15-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |